Lung cancer is the most common cancer in the world but still remains a challenge both in the clinical and research settings. From studying the biology of lung cancer cells in the lab to leading clinical trials testing cutting-edge treatments, Roche is committed to addressing the medical need for therapies that extend patients’ lives.
ESMO IO 2019
Impact of digital patient monitoring (DPM) on quality of clinical care of cancer immunotherapy (CIT)-treated patients (pts) with advanced/metastatic non-small cell lung cancer (a/mNSCLC)
A drug- and indication-specific module for the Kaiku digital patient monitoring (DPM) platform was co-developed with patients and healthcare professionals (HCPs) for cancer immunotherapy-treated patients with advanced/metastatic non-small cell lung cancer. A pilot study was conducted to assess user experience, overall satisfaction and the impact of the DPM tool on clinical care. This poster reports results from patient and HCP surveys, as well as HCP interviews, over a minimum of three months of DPM tool use.
Clinical efficacy of ▼atezolizumab in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
IMpower110 is a randomized, Phase III study of atezolizumab monotherapy vs platinum-based chemotherapy in PD-L1–selected, chemo-naive patients with metastatic NSCLC. Efficacy analyses in key pre-specified subgroups in IMpower110, defined by the 22C3 and SP263 PD-L1 IHC and bTMB assays are reported
ESMO Asia 2019
Entrectinib in Locally Advanced/Metastatic ROS1 and NTRK Fusion-Positive Non-Small Cell Lung Cancer (NSCLC): Updated Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Entrectinib is a potent and selective ROS1/NTRK/ALK tyrosine kinase inhibitor. This is an update to the integrated analysis from three Phase 1/2 entrectinib trials for adults with NTRK fusion-positive or ROS1 fusion-positive NSCLC after an additional 5 months of follow-up.
Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Entrectinib is an oral, CNS-active, potent and selective inhibitor of kinases encoded by ROS1, NTRK and ALK genes. It was specifically designed to cross the blood–brain barrier and remain within the CNS and is a more potent ROS1 inhibitor than crizotinib. This is an analysis of the incidence of brain metastases and the treatment patterns of patients with ROS1-positive NSCLC.
Updated Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Tumors: Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Entrectinib is a potent and selective ROS1/NTRK/ALK tyrosine kinase inhibitor. This is an update to the integrated analysis from three Phase 1/2 entrectinib trials for adults with NTRK fusion-positive solid tumors after an additional 5 months of follow-up.
Matching-adjusted indirect comparison of entrectinib versus crizotinib in ROS1 NSCLC patients
A matching-adjusted indirect comparison of in ROS1 NSCLC patients to identify published literature on treatments for patients with ROS1-positive NSCLC and estimate the relative efficacy and safety of entrectinib compared to crizotinib.
Health and budget impact of comprehensive genomic profiling in lung cancer in Canada
The current Canadian genomic testing landscape for NSCLC comprises single-gene and multigene hotspot panels that examine selected regions of the genome. Comprehensive genomic profiling (CGP) utilizes next-generation sequencing to detect known and novel variants across four main classes of genomic alterations. The objective of this analysis was to assess health and budget impact of adopting CGP for NSCLC in Canada.
Methodological approaches for incorporating real-world overall survival data into long-term survival estimates: a case study of a NICE technology appraisal in extensive-stage Small-Cell Lung Cancer
This case study of a NICE technology appraisal presents different methodological approaches to incorporating Flatiron Health RWD and IMpower133 RCT data into cost-effectiveness modelling, improving estimates of long-term survival for patients with extensive-stage small-cell lung cancer treated with chemotherapy
IMpower110: Interim overall survival (OS) analysis of a Phase III study of atezolizumab (atezo) monotherapy vs platinum-based chemotherapy (chemo) as first-line (1L) treatment in PD-L1–selected NSCLC
IMpower110 is a randomized, open-label, multicenter Phase III study of atezo vs platinum-based chemotherapy in PD-L1–selected, chemo-naive patients with stage IV NSCLC. The primary endpoint of OS, key secondary endpoints and safety are presented.
Phase 1/2 trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (cns) tumours
Entrectinib is a selective, brain penetrant inhibitor with potency against TRKA/B/C, ROS1 and ALK currently in clinical development for the treatment of tumors harboring NTRK or ROS1 gene fusions. Here, the primary efficacy and safety data from the pivotal phase 1/2 paediatric study are presented.